For research use only. Not for therapeutic Use.
BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a KD value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A, but weak or no activity against cancer cells with a low expression level of BAZ1A[1].
BAZ1A-IN-1 (Cpd-2) (0.015-100 μM; 96 hours) exhibits good anti-viability activity against all the four cancer cell lines that have a high expression level of BAZ1A, with IC50 values of 5.08 μM, 4.29 μM, 10.65 μM, and 7.70 μM for THP-1, ZR-75-30, BT474, and H1975 cells, respectively[1].
Catalog Number | I045222 |
CAS Number | 941521-45-5 |
Synonyms | 1-(3-nitrophenyl)-3-(4-phenyl-1,3-thiazol-2-yl)urea |
Molecular Formula | C16H12N4O3S |
Purity | ≥95% |
InChI | InChI=1S/C16H12N4O3S/c21-15(17-12-7-4-8-13(9-12)20(22)23)19-16-18-14(10-24-16)11-5-2-1-3-6-11/h1-10H,(H2,17,18,19,21) |
InChIKey | UJRJAZDAWUSWRK-UHFFFAOYSA-N |
SMILES | C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)NC3=CC(=CC=C3)[N+](=O)[O-] |
Reference | [1]. Yang Z, et al. Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening and activity evaluation. Bioorg Med Chem Lett. 2021;33:127745. |